KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D
- University of Helsinki, Finland
- Max Planck Institute for Heart and Lung Research, Germany
- Wihuri Research Institute, Finland
Abstract
Vascular endothelial growth factor-C (VEGF-C) acts primarily on endothelial cells, but also on non-vascular targets, e.g. in the CNS and immune system. Here we describe a novel, unique VEGF-C form in the human reproductive system produced via cleavage by kallikrein-related peptidase 3 (KLK3), aka prostate-specific antigen (PSA). KLK3 activated VEGF-C specifically and efficiently through cleavage at a novel N-terminal site. We detected VEGF-C in seminal plasma, and sperm liquefaction occurred concurrently with VEGF-C activation, which was enhanced by collagen and calcium binding EGF domains 1 (CCBE1). After plasmin and ADAMTS3, KLK3 is the third protease shown to activate VEGF-C. Since differently activated VEGF-Cs are characterized by successively shorter N-terminal helices, we created an even shorter hypothetical form, which showed preferential binding to VEGFR-3. Using mass spectrometric analysis of the isolated VEGF-C-cleaving activity from human saliva, we identified cathepsin D as a protease that can activate VEGF-C as well as VEGF-D.
Data availability
All data generated or analysed during this study are included in the manuscript and supporting files.
Article and author information
Author details
Funding
Academy of Finland (265982)
- Michael Jeltsch
European Research Council (Horizon 2020 Research and Innovation programme 743155)
- Kari Alitalo
Wihuri Research Institute
- Kari Alitalo
Academy of Finland Centre of Excellence Program 2014-2019 (307366)
- Kari Alitalo
Novo Nordisk Foundation
- Kari Alitalo
Cancer Society of Finland
- Sawan Kumar Jha
Biomedicum Helsinki-säätiö
- Sawan Kumar Jha
Päivikki and Sakari Sohlberg Foundation
- Khushbu Rauniyar
Wihuri Research Institute
- Sawan Kumar Jha
Academy of Finland (272683)
- Michael Jeltsch
Academy of Finland (273612)
- Michael Jeltsch
Finnish Foundation for Cardiovascular Research
- Michael Jeltsch
Academy of Finland (273817)
- Michael Jeltsch
Jane ja Aatos Erkon Säätiö
- Michael Jeltsch
Cancer Society of Finland
- Michael Jeltsch
Magnus Ehrnroothin Säätiö
- Michael Jeltsch
K Albin Johansson Foundation
- Michael Jeltsch
Integrated Life Science Doctoral Program
- Sawan Kumar Jha
Sigrid Jusélius Foundation
- Hannu Koistinen
Laboratoriolääketieteen edistämissäätiö
- Hannu Koistinen
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Gou Young Koh, Institute of Basic Science and Korea Advanced Institute of Science and Technology (KAIST), Korea (South), Republic of
Ethics
Animal experimentation: All animal experiments carried out in this study were performed according to guidelines and regulations approved by the National Board for Animal Experiments of the Provincial State Office of Southern Finland (ESAVI/7012/04.10.07/2016).
Version history
- Received: January 2, 2019
- Accepted: May 16, 2019
- Accepted Manuscript published: May 17, 2019 (version 1)
- Version of Record published: June 21, 2019 (version 2)
Copyright
© 2019, Jha et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,189
- views
-
- 365
- downloads
-
- 33
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
KLK3/PSA and cathepsin D activate VEGF-C and VEGF-D
eLife 8:e44478.
https://doi.org/10.7554/eLife.44478
Further reading
-
- Cancer Biology
- Cell Biology
High-throughput vertebrate animal model systems for the study of patient-specific biology and new therapeutic approaches for aggressive brain tumors are currently lacking, and new approaches are urgently needed. Therefore, to build a patient-relevant in vivo model of human glioblastoma, we expressed common oncogenic variants including activated human EGFRvIII and PI3KCAH1047R under the control of the radial glial-specific promoter her4.1 in syngeneic tp53 loss-of-function mutant zebrafish. Robust tumor formation was observed prior to 45 days of life, and tumors had a gene expression signature similar to human glioblastoma of the mesenchymal subtype, with a strong inflammatory component. Within early stage tumor lesions, and in an in vivo and endogenous tumor microenvironment, we visualized infiltration of phagocytic cells, as well as internalization of tumor cells by mpeg1.1:EGFP+ microglia/macrophages, suggesting negative regulatory pressure by pro-inflammatory cell types on tumor growth at early stages of glioblastoma initiation. Furthermore, CRISPR/Cas9-mediated gene targeting of master inflammatory transcription factors irf7 or irf8 led to increased tumor formation in the primary context, while suppression of phagocyte activity led to enhanced tumor cell engraftment following transplantation into otherwise immune-competent zebrafish hosts. Altogether, we developed a genetically relevant model of aggressive human glioblastoma and harnessed the unique advantages of zebrafish including live imaging, high-throughput genetic and chemical manipulations to highlight important tumor-suppressive roles for the innate immune system on glioblastoma initiation, with important future opportunities for therapeutic discovery and optimizations.
-
- Cancer Biology
- Cell Biology
Establishing a zebrafish model of a deadly type of brain tumor highlights the role of the immune system in the early stages of the disease.
